NLS Pharmaceutics (NLSP) and Kadimastem announced that Kadimastem has issued a notice to convene a special general meeting of Kadimastem’s shareholders to approve the merger transaction with NLS. The Central District Court in Israel has approved that this meeting may occur within a reduced time frame of only 14 days from the date of publication of the meeting notice. This meeting is needed to secure Kadimastem’s shareholder approval which are critical to completing the merger process.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising
- NLS Pharmaceutics Shareholders Approve Meeting Agenda
- NLS Pharmaceutics and Kadimastem Move Forward with Merger Plans
- NLS Pharmaceutics, Kadimastem announce filing of F-4 Registration Statement
- NLS Pharmaceutics Calls Extraordinary Meeting for Major Capital Restructuring